Neogenomics stock gets MolDX reimbursement for cancer test By Investing.com

Key event: MolDX reimbursement approved at $3,289 per PanTracer LBx CGP test effective March 10, enabling three weeks of Q1 and a full Q2 quarter of revenues above current guidance. NeoGenomics reported Q4 2025 EPS $0.06 vs $0.04 consensus (+50% surprise) and revenue $190.17M vs $188.14M, while shares trade at $7.88 (down 33% YTD). Analysts/shops reacted favorably—Needham raised its price target to $15 (Buy) and Leerink reiterated Market Perform $14—and analysts expect the company to reach profitability this year; management's 2026 revenue and EBITDA guidance aligns with consensus. The reimbursement and CMS coverage materially de-risk near-term revenue visibility and are likely to move the stock at the company level.

Analysis

Third-party coverage materially lowers commercialization risk for an NGS lab and shifts the value discussion from “future potential” to near-term cash conversion and margin expansion. Because coverage directly reduces patient out-of-pocket friction, utilization is the primary scaling lever; expect utilization rates to migrate materially higher over the next 2-6 quarters if clinician ordering patterns and lab turn-times remain steady. The immediate accounting effect is front-loaded revenue recognition versus prior internal plans, which compresses the path to EBITDA breakeven and converts a narrative trade into a fundamentals-driven re-rating opportunity.

This creates asymmetric competitive dynamics: an operator with an established national lab network gains unit-cost advantage and faster sample logistics, putting pressure on smaller regional players and any competitors that rely on outsourced processing. Payer precedent also lowers pricing uncertainty industry-wide, which can trigger consolidation (accretion for scale buyers, margin pressure for fragmentary players). Conversely, input-cost volatility for sequencing reagents and potential payer policy reversals are direct margin levers that can swing outcomes by high-single-digit EBITDA points.

Key catalysts and tail risks are near-term and idiosyncratic: expect material share price moves around the next quarterly revenue cadence, any retroactive payment resolution, and competitor contracting announcements over the next 3–9 months. Tail risks that could reverse the thesis include a payer carve-out, a workflow/turnaround degradation that stalls clinician adoption, or a quick competitive price response that erodes realized per-test economics. Monitor utilization growth, realized ASPs, and reagent cost per test as leading indicators of sustained upside.

Key Decisions for Investors

• Initiate a scale-in long position in NEO over the next 10 trading days (build to target weight in 3 tranches). Hedge initial exposure with a protective put (3–6 month tenor) sized to limit downside to ~25–30% of position value; upside targeting 50–100% over 6–12 months if utilization and ASPs normalize above guidance.
• Buy a 4–6 month call spread on NEO (debit vertical) sized for ~3x upside vs premium if Q2 revenue and retro-pay announcements beat expectations; this limits capital at risk while capturing re-rating into next guidance cycle.
• Pair trade: long NEO / short GH (Guardant Health) equal-dollar exposure for a 6–12 month horizon to isolate reimbursement-driven fundamentals vs multiple compression risk in a high-multiple peer. Close if NEO utilization lags by >20% QoQ or if GH announces a material commercial win that changes payer dynamics.
• Event hedge: if a retroactive reimbursement decision is delayed beyond the next quarter, buy short-dated puts or cut exposure—this is the primary single-point risk that can erase near-term upside and should be monitored daily.